Logo

Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-Cell Lymphoma

Share this

Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-Cell Lymphoma

Shots:

  • The EC has granted conditional marketing authorization to Zynlonta for the treatment of r/r DLBCL
  • The approval was based on data from the P-II trial (LOTIS-2) evaluating Zynlonta in 145 adult patients with r/r DLBCL, following two or more prior lines of systemic therapy. The results showed an ORR of (48.3%) incl. CR rate of 24.1% and a PR rate of 24.1%, patients had a median time to response of 1.3mos. and m-DoR for the 70 responders was 10.3mos.
  • The EC’s decision will be valid in all EU member states, Iceland, Norway & Liechtenstein. Sobi & ADC Therapeutics collaborated to develop and commercialize Zynlonta for use in haematology and other indications in the EU and most international markets 

Ref: Prnewswire | Image: ADC Therapeutics

Related Posts:- ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in EU and Select International Territories

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions